Baker Avenue Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Baker Avenue Asset Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-25	Closed	-$950	–	1768
2022 Q4	$950	Buy	+25	New	+$860	﹤0.01%	1115

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baker Avenue Asset Management's RETA Position: Q1 2023 in Review

Baker Avenue Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2023, closing a stake of 25 shares — an estimated $950 sold.

Baker Avenue Asset Management first reported a position in RETA in Q4 2022 and held it in 1 quarter. The position peaked at $950 in Q4 2022. 205 funds tracked by Wall St. Rank hold RETA as of Q1 2023.

Baker Avenue Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
Baker Avenue Asset Management sold 25 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2023, an estimated $950.
Baker Avenue Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2022 and held it in 1 quarter.
Baker Avenue Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $950 in Q4 2022.
205 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2023.

Based on Baker Avenue Asset Management's 13F filing for Q1 2023, filed 16 May 2023.